Metabolic dysfunction-associated steatotic liver disease(MASLD),previously known as non-alcoholic fatty liver disease(NAFLD),has emerged as a leading cause of chronic liver disease globally,reflecting the convergence ...Metabolic dysfunction-associated steatotic liver disease(MASLD),previously known as non-alcoholic fatty liver disease(NAFLD),has emerged as a leading cause of chronic liver disease globally,reflecting the convergence of rising obesity,insulin resistance,and type 2 diabetes mellitus(1).The disease burden is not only liver-related but systemic,contributing to increased cardiovascular risk,malignancy,and reduced quality of life(2).The clinical spectrum of MASLD ranges from simple steatosis to metabolic dysfunction-associated steatohepatitis(MASH),fibrosis,and cirrhosis,with a growing share of hepatocellular carcinoma cases now being attributed to MASLD rather than viral etiologies(3).MASLD pathophysiology involves a complex interplay of chronic low-grade inflammation,immune cell activation,and systemic metabolic dysfunction,implicating organs beyond the liver,including adipose tissue and spleen(2,3).展开更多
The prevalence of cirrhosis and hepatocellular carcinoma resulting from metabolic dysfunction-associated steatotic liver disease(MASLD)is increasing,posing a significant burden on both the economy and public health(1,...The prevalence of cirrhosis and hepatocellular carcinoma resulting from metabolic dysfunction-associated steatotic liver disease(MASLD)is increasing,posing a significant burden on both the economy and public health(1,2).Although the need for effective therapeutic strategies for MASLD is growing,pharmacologic options remain limited,with resmetirom currently the only approved drug.Consequently,lifestyle modification-particularly weight reduction through diet and exercise-remains the cornerstone of MASLD management.展开更多
文摘Metabolic dysfunction-associated steatotic liver disease(MASLD),previously known as non-alcoholic fatty liver disease(NAFLD),has emerged as a leading cause of chronic liver disease globally,reflecting the convergence of rising obesity,insulin resistance,and type 2 diabetes mellitus(1).The disease burden is not only liver-related but systemic,contributing to increased cardiovascular risk,malignancy,and reduced quality of life(2).The clinical spectrum of MASLD ranges from simple steatosis to metabolic dysfunction-associated steatohepatitis(MASH),fibrosis,and cirrhosis,with a growing share of hepatocellular carcinoma cases now being attributed to MASLD rather than viral etiologies(3).MASLD pathophysiology involves a complex interplay of chronic low-grade inflammation,immune cell activation,and systemic metabolic dysfunction,implicating organs beyond the liver,including adipose tissue and spleen(2,3).
基金supported by Japan Agency for Medical Research and Development(JP25fk0210123 to M.K.)Japanese Ministry of Health,Labour and Welfare(23HC2001 to M.K.)+1 种基金from Japan Agency for Medical Research and Development(JP25fk0310535,JP25fk0210174,and JP25fk0210123 to N.T.)Japanese Ministry of Health,Labour and Welfare(23HC2003 and 23HC2002 to N.T.).
文摘The prevalence of cirrhosis and hepatocellular carcinoma resulting from metabolic dysfunction-associated steatotic liver disease(MASLD)is increasing,posing a significant burden on both the economy and public health(1,2).Although the need for effective therapeutic strategies for MASLD is growing,pharmacologic options remain limited,with resmetirom currently the only approved drug.Consequently,lifestyle modification-particularly weight reduction through diet and exercise-remains the cornerstone of MASLD management.
